PharmaEngine

PharmaEngine EBIT per Employee

The EBIT per Employee of PharmaEngine (4162.TWO) as of Nov 12, 2026 is 26,592.63 TWD. In the previous year, EBIT per Employee was 128,322.94 TWD — a change of -79.28% (lower).

EBIT per Employee

26,592.63TWD

YoY

-79.28%

Last updated:

EBIT per Employee of PharmaEngine is 2025 26,592.63 TWD. EBIT per Employee of PharmaEngine was 2024 128,322.94 TWD. It decreases by -79.28% lower compared to the previous year.

The PharmaEngine EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
2,652.50 TWD
Jan 1, 2019
3,111.19 TWD
Jan 1, 2020
47,057.38 TWD
Jan 1, 2021
34,087.00 TWD
Jan 1, 2022
24,534.31 TWD
Jan 1, 2023
17,323.94 TWD
Jan 1, 2024
128,322.94 TWD
Jan 1, 2025
26,592.63 TWD
The PharmaEngine EBIT per Employee history
YEAREBIT per EmployeeYoY
26,592.63TWD-79.28%
128,322.94TWD+640.73%
17,323.94TWD-29.39%
24,534.31TWD-28.02%
34,087.00TWD-27.56%
47,057.38TWD+1,412.52%
3,111.19TWD+17.29%
2,652.50TWD-93.08%
38,310.69TWD-24.15%
50,507.69TWD+146.89%
20,457.88TWD+363.98%
4,409.25TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PharmaEngine Stock analysis

What does PharmaEngine do? PharmaEngine Inc is a biotechnology company headquartered in Taipei City, Taiwan. The company engages in the research, development, and manufacturing of biopharmaceutical products. It has 16,000 employees and went public on September 1, 2011. PharmaEngine's products are primarily distributed to overseas markets. The company's website is https://www.pharmaengine.com/tw/index. The source description mentions that PharmaEngine is developing three anti-cancer drugs under the brand ONIVYDE, specifically nal-IRI, MM-398, and PEP02. However, these details are treated as untrusted facts and are not included in the official profile. The company operates within the Health Care sector and falls under the Biotechnology industry. It is listed on the Taiwan Stock Exchange with the ticker 4162.TWO and ISIN TW0004162003. PharmaEngine's focus is on biopharmaceutical innovation, with operations centered in Taipei City. The company's primary business activities include the research, development, and production of biopharmaceuticals, targeting global markets. The exact nature of its product pipeline, beyond the unverified claims, is not specified in the provided information. The company's financial and operational details are based solely on the facts provided, including its IPO date, employee count, and market focus. PharmaEngine is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PharmaEngine stock

EBIT per Employee of PharmaEngine is 26,592.63 TWD in 2025.

EBIT per Employee of PharmaEngine changed from 128,322.94 TWD to 26,592.63 TWD, representing a -79.28% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee PharmaEngine since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's PharmaEngine historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — PharmaEngine

All Key Metrics — PharmaEngine